Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

share with twitter share with LinkedIn share with facebook
share via e-mail
05/16/2012 | 11:11am CEST

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
03:18p Cross-border M&A between U.S. and European firms at 10 year high
10:24a JOHNSON & JOHNSON : Canadian Concerns Over Surgical Mesh Recalls and Usage on th..
05/21 JOHNSON & JOHNSON : Talcum powder lawsuits find a home in St. Louis -- for now
05/20 REP. PAYNE ISSUES : Johnson & Johnson's Commitment to Veterans
05/20 Corticosteroids Market 2017 - GSK, Cipla, Sumitomo, Pfizer, Novartis, Merck, ..
05/19 JOHNSON & JOHNSON : Xian Arm Invests More for Lung Diseases
05/19 JOHNSON & JOHNSON : Amey joins businesses campaigning to support social enterpri..
05/18 JOHNSON & JOHNSON : Loses Another Talcum Powder Lawsuit, As Missouri Jury Awards..
05/18 JOHNSON & JOHNSON : Pennsylvania Transvaginal Mesh Lawsuit Plaintiffs Hope to Ex..
05/18 JOHNSON & JOHNSON : RM Global to invest $30m in FutuRx biotech startups
More news
Sector news : Pharmaceuticals - NEC
08:32aDJASTRAZENECA : in Pact with Recordati for Heart-Drug Seloken in Europe
05/19 European shares claw back gains after worst week in six months
05/19 FTSE climbs for fourth straight week, shrugging off Trump slump
05/19 Hikma trims full year revenue forecast on Advair U.S. launch delay
05/18 NOVARTIS : to cut around 500 jobs in Switzerland, add 350
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11:05a RETIREMENT STRATEGY : Yes, I Am A Little Nuts But I Am Doing It Anyway
07:43a My 83 Stock Portfolio Requirements And Listing Of Do Not Sell, Core And Specu..
02:45a Tracking Tweedy Browne Portfolio - Q1 2017 Update
05/20 RETIREMENT STRATEGY : Now Is Not The Time To Bury Your Head In The Sand
Financials ($)
Sales 2017 75 617 M
EBIT 2017 23 468 M
Net income 2017 17 895 M
Debt 2017 8 113 M
Yield 2017 2,65%
P/E ratio 2017 19,37
P/E ratio 2018 17,40
EV / Sales 2017 4,63x
EV / Sales 2018 4,40x
Capitalization 342 117 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 130 $
Spread / Average Target 2,6%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.23%342 117
ROCHE HOLDING LTD.14.79%235 098
NOVARTIS AG6.28%210 347
PFIZER INC.-0.06%193 303
MERCK & CO., INC.8.34%174 449
SANOFI14.93%124 751
More Results